MALDI-TOF Biotyper Sirius
| Location: | Illinois |
|---|---|
| Posted: | Mar 30, 2026 |
| Due: | Mar 10, 2026 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | 75F40126R00030 |
| Publication URL: | To access bid details, please log in. |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Combined Synopsis/Solicitation (Original)
- Original Published Date: Mar 30, 2026 04:06 pm EDT
- Original Date Offers Due: Mar 10, 2026 12:00 pm EDT
- Inactive Policy: 15 days after date offers due
- Original Inactive Date: Mar 25, 2026
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code: 6640 - LABORATORY EQUIPMENT AND SUPPLIES
-
NAICS Code:
- 334516 - Analytical Laboratory Instrument Manufacturing
-
Place of Performance:
Summit Argo , IL 60501USA
The select agent laboratory at Moffett participates in the Laboratory Response Network (LRN) for detecting botulinum neurotoxins (BoNTs). Traditional mouse bioassays, though the gold standard, are costly, slow, and raise ethical concerns. Previously, DIG-ELISA kits were used for high-throughput screening to reduce animal use, but these kits are being phased out in favor of the Endopep-MS (Endopeptidase–Mass Spectrometry) assay.
Developed over 10 years by CDC’s Biological Mass Spectrometry Laboratory, the Endopep-MS assay detects BoNT activity on peptide substrates that mimic the toxin’s natural targets. This method eliminates animal testing and allows high-throughput analysis, supporting rapid response in large-scale events.
The FDA requires one (1) Bruker MALDI-TOF Biotyper Sirius one GP system to replace an obsolete instrument. The system must support Endopep-MS assays for detection, differentiation, and characterization of Clostridium botulinum neurotoxins, maintaining operational capability critical to mission readiness and public health protection.
- 11601 Landsdown St Floor 13
- Rockville , MD 20852
- USA
- Erika Crawford
- erika.crawford@fda.hhs.gov
- Phone Number 3017960298
- Mar 30, 2026 04:06 pm EDTCombined Synopsis/Solicitation (Original)
With GovernmentContracts, you can:
- Find more opportunities and win more business
- Receive daily alerts for all new bid opportunities
- Get contract opportunities matched to your business